

## Datasheet: PIP014

<b>Description:</b>	NATIVE MUMPS VIRUS
<b>Name:</b>	MUMPS VIRUS
<b>Format:</b>	Inactivated Pathogen
<b>Product Type:</b>	Antigen
<b>Quantity:</b>	1 ml

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Viral
<b>Product Form</b>	Inactivated Mumps virus - liquid
<b>Preparation</b>	Mumps virus, Enders strain, cultured in BSC-1 cells. Optimally infected cells are harvested, disrupted by sonication in culture medium and subjected to low speed centrifugation. The supernatant from the infected culture is concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material.
<b>Buffer Solution</b>	Culture medium 1969B
<b>Preservative Stabilisers</b>	None present
<b>Approx. Protein Concentrations</b>	Current, batch-specific concentration 1.0 mg/ml
<b>External Database Links</b>	<b>UniProt:</b> <a href="https://www.uniprot.org/uniprot/P21277">P21277</a> <a href="#">Related reagents</a>

<b>Synonyms</b>	NP
<b>Product Information</b>	<p><b>Native mumps virus preparation</b> Native mumps virus contains a high concentration of virus and viral components. The preparation also contains some cellular material suspended in tissue culture medium (1969B).</p> <p>Mumps virus is a member of the <i>Paramyxoviridae</i> family and is the causative agent of mumps. Mumps is most typically characterised by painful swelling of the salivary glands and fever. In some adult men, the virus might also infect the testicles, rarely causing sterility. The virus is spread by airborne droplets from the nose or throat and can have an incubation period of up to three weeks. Infected individuals are contagious from approximately 6 days before until about 9 days after the onset of symptoms. The disease is self-limiting and treatment involves controlling specific symptoms. An effective vaccine exists and may be given separately or as part of the MMR vaccine.</p>
<b>Activity</b>	Antigenic activity is 51.1% of internal reference batch
<b>Instructions For Use</b>	PIP014 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.
<b>References</b>	<ol style="list-style-type: none"> <li>1. Bhoj, V.G. <i>et al.</i> (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. <a href="#">Blood. 128 (3): 360-70.</a></li> <li>2. Riggerbach, M.M. <i>et al.</i> (2021) Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents. <a href="#">Clin Immunol. 234: 108912.</a></li> <li>3. Böröcz, K. <i>et al.</i> (2022) Dynamic Features of Herd Immunity: Similarities in Age-Specific Anti-Measles Seroprevalence Data between Two Countries of Different Epidemiological History. <a href="#">J Clin Med. 11(4):1145.</a></li> <li>4. Wang, L. <i>et al.</i> (2023) Associations of adaptive immune cell subsets with measles, mumps, and Rubella–Specific immune response outcomes <a href="#">Heliyon. 9 (12): e22998.</a></li> <li>5. Ovsyannikova, I.G. <i>et al.</i> (2023) Genome-wide determinants of cellular immune responses to mumps vaccine. <a href="#">Vaccine. 41 (44): 6579-88.</a></li> <li>6. Szinger, D. <i>et al.</i> (2023) Following Natural Autoantibodies: Further Immunoserological Evidence Regarding Their Silent Plasticity and Engagement in Immune Activation. <a href="#">Int J Mol Sci. 24 (19)Oct 06 [Epub ahead of print].</a></li> <li>7. Szinger, D. <i>et al.</i> (2024) Raising Epidemiological Awareness: Assessment of Measles/MMR Susceptibility in Highly Vaccinated Clusters within the Hungarian and Croatian Population—A Sero-Surveillance Analysis <a href="#">Vaccines. 12 (5): 486.</a></li> </ol>
<b>Storage</b>	<p>Store at -70°C.</p> <p>Storage in frost-free freezers is not recommended.</p> <p>This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.</p>
<b>Guarantee</b>	12 months from date of despatch
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10286 available at: <a href="https://www.bio-rad-antibodies.com/SDS/PIP014">https://www.bio-rad-antibodies.com/SDS/PIP014</a>

10286

This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.

---

**Regulatory**

For research purposes only

---

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M421173:230706'

**Printed on 06 May 2024**

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)